Quest Diagnostics (DGX) raised its guidance ranges for 2026 revenue and adjusted diluted EPS with its Q3 earnings release. - The company sees full-year revenue of between $12.065B and $12.105B, compared to $11.95B to $12.05B prior. Adjusted diluted EPS is projected at betw
Quest Diagnostics (DGX) raised its guidance ranges for 2026 revenue and adjusted diluted EPS with its Q3 earnings release. – The company sees full-year revenue of between $12.065B and $12.105B, compared to $11.95B to $12.05B prior.
Adjusted diluted EPS is projected at between $11.25
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
